Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) fell 10.9% in the afternoon session after the company reported disappointing fourth-quarter results: EPS missed analysts' expectations ...

M&T Bank Corp increased its stake in shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 9.4% during the 4th ...

Biotechnology company United Therapeutics (NASDAQ:UTHR) in Q4 CY2024, with sales up 19.7% year on year to $735.9 million. Its GAAP profit of $6.19 per share was 1.2% below analysts’ consensus ...

StockNews.com lowered shares of United Therapeutics (NASDAQ:UTHR – Free Report) from a strong-buy rating to a buy rating in a ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., March 04, 2025--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that ...

In a report released yesterday, Tiago Fauth from Wells Fargo maintained a Buy rating on United Therapeutics (UTHR – Research Report), with a ...

Despite risks from patent expirations and legal challenges, UTHR's diversified portfolio and strong financials position it well for sustained growth. Any investor who wants to invest money in the ...

UNITED THERAPEUTICS ($UTHR) posted quarterly earnings results on Wednesday, February 26th. The company reported earnings of $6.19 per share, missing estimates of $6. ...

In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against the other cheap biotech stocks. Biotechnology stocks are among the most volatile ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on United Therapeutics (UTHR – Research Report) and ...